Kidney Cancer Prognosis: Survival Rates by Stage, Age & Treatment

Renal cell carcinoma (RCC) prognosis depends primarily on anatomic stage at diagnosis, with modifiers for histology, grade, performance status, and treatment access.

5-Year Relative Survival by Stage (SEER 2013–2019)

StageDescription5-Yr Survival
Localized (I–II)Confined to kidney93%
Regional (III)Perinephric fat, renal vein, adrenal, nodes72%
Distant (IV)Metastatic (lung, bone, liver, brain)15%
All stages combined—77%

Prognostic Modifiers

  • Age: <50 yr better than >70 yr (comorbidities, treatment tolerance).
  • Histology: Clear cell (most common); papillary, chromophobe have better outlook; sarcomatoid/rhabdoid = aggressive.
  • Grade (Fuhrman/ISUP): Grade 1–2 vs 3–4.
  • Performance status (ECOG/Karnofsky) – Fitness for systemic therapy.
  • MSKCC / IMDC Risk Models (metastatic): Hgb, Ca, neutrophils, platelets, time from diagnosis, KPS.

Treatment Impact on Survival

  • Surgery (partial/radical nephrectomy) – Curative for localized disease; 5-yr CSS >90% for pT1a.
  • Ablation (RFA/cryo) – For small tumors <3 cm in poor surgical candidates.
  • Systemic therapy (metastatic): VEGF-TKIs (sunitinib, pazopanib), IO combinations (nivo+ipi, pembro+axitinib), HIF-2α inhibitor (belzutifan). Median OS now >40 months in favorable IMDC risk.
  • Radiation / SBRT – Oligometastatic disease, palliation.

Follow-Up

  • Post-nephrectomy: CT chest/abdomen q6–12mo × 3 yr, then annually.
  • Metastatic: Imaging q8–12 wks on therapy.

Discuss your specific stage, histology, and comorbidities with your oncology team for personalized prognosis.

Kidney Disease - Related Articles